FDA Warns Novo Nordisk That DTC Ad for Wegovy Pill Includes Misleading Claims
- February 13, 2026
The Food and Drug Administration (FDA) is warning Novo Nordisk Inc. that a television advertisement for the new Wegovy tablet includes false or misleading claims suggesting the pill form is superior to other GLP-1 treatments for weight loss.
ARTICLE TAGS
You must be logged in to access this content.